From evidence to action
At ICARS, our mission is to partner with Low- and Middle-income countries (LMICs) in their efforts to reduce drug-resistant infections. We do this by co-developing tailored solutions with LMIC governments and researchers, who then implement them on the ground using ICARS funding and expertise, building on AMR National Action Plans.
Follow us and view our latest news
ICARS – A Year in Review
ICARS is excited to share its key highlights and achievements in 2023 in the Year in Review report! In 2023, ICARS underwent significant organisational maturation, building upon the groundwork laid in preceding years. As our Executive Director took office, our expansion continued through collaborations with partners to implement and develop projects and activities, while also enhancing evidence generation to inform policy. We initiated new partnerships and strengthened existing ones nationally, regionally, and globally to advocate for country-owned antimicrobial resistance (AMR) solutions, alongside efforts to reinforce capacity and capabilities in Low- and Middle-Income Countries (LMICs). Additionally, we successfully attracted new donors to support our mission and activities. To learn more about ICARS’ highlights in 2023, read the document below.
ICARS Strategy 2022 – 2026
Guided by our vision of a world without drug-resistant infections, we have developed a new strategy with a revised outcome framework and refined the scope and goals of each of our interconnected pillars.
We are pleased to present a succinct overview of ICARS unique value proposition, followed by our overarching strategy that will run until 2026, as well as a roadmap that details our planned activities per pillar.
Our projects inform policy and practice around the world
ICARS works with Low- and Middle-Income Countries around the world to tackle antimicrobial resistance and support the implementation of their AMR National Action Plans.
Join our mission
To achieve sustainable change in LMICs, we invite countries and foundations to join us as Strategic Funding Partners, Funding Partners or Mission Partners, in a truly international effort to mitigate antimicrobial resistance.
Please do not hesitate to contact our team for further information.
